Since we observed, in our tumor samples, that PTCs harboring the BRAFV600E mutation presented higher levels of phospho-AKT Ser473, we were also interested in the effect of the BRAFV600E mutation in the activation status of each mTOR complex. This evidence concerns the gene AKT1 and neoplasm.